377 related articles for article (PubMed ID: 27196673)
1. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
[TBL] [Abstract][Full Text] [Related]
2. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
3. Development and persistence of DAA resistance associated mutations in patients failing HCV treatment.
Paolucci S; Fiorina L; Mariani B; Landini V; Gulminetti R; Novati S; Maserati R; Barbarini G; Bruno R; Baldanti F
J Clin Virol; 2015 Nov; 72():114-8. PubMed ID: 26489401
[TBL] [Abstract][Full Text] [Related]
4. Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning.
Cuypers L; Libin P; Schrooten Y; Theys K; Di Maio VC; Cento V; Lunar MM; Nevens F; Poljak M; Ceccherini-Silberstein F; Nowé A; Van Laethem K; Vandamme AM
Infect Genet Evol; 2017 Sep; 53():15-23. PubMed ID: 28499845
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
6. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Tao W; Gan T; Lu J; Zhong J
Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
[TBL] [Abstract][Full Text] [Related]
7. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy.
Chayama K; Hayes CN
Viruses; 2015 Oct; 7(10):5328-42. PubMed ID: 26473914
[TBL] [Abstract][Full Text] [Related]
8. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
[TBL] [Abstract][Full Text] [Related]
9. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.
Roche B; Coilly A; Roque-Afonso AM; Samuel D
Viruses; 2015 Sep; 7(9):5155-68. PubMed ID: 26404355
[TBL] [Abstract][Full Text] [Related]
10. The role of resistance in HCV treatment.
Vermehren J; Sarrazin C
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
12. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy of hepatitis C in 2014: do we need resistance testing?
Schneider MD; Sarrazin C
Antiviral Res; 2014 May; 105():64-71. PubMed ID: 24583028
[TBL] [Abstract][Full Text] [Related]
15. Which therapeutic option for hepatitis C virus genotype 1?
Brochot E; Helle F; François C; Castelain S; Capron D; Nguyen-Khac E; Duverlie G
Scand J Gastroenterol; 2015 Apr; 50(4):470-8. PubMed ID: 25396710
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
[TBL] [Abstract][Full Text] [Related]
17. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
18. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data.
Hong CM; Liu CH; Su TH; Yang HC; Chen PJ; Chen YW; Kao JH; Liu CJ
J Microbiol Immunol Infect; 2020 Aug; 53(4):569-577. PubMed ID: 30316726
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
